Ceebraid-Signal

Ceebraid-Signal was a biotechnology company focused on the discovery and development of small molecule therapeutics targeting signal transduction pathways. The company specialized in the development of inhibitors for cyclin-dependent kinases (CDKs) and c-Jun N-terminal kinases (JNKs) to treat cancer and inflammatory conditions. Its research efforts were centered on modulating intracellular signaling to address unmet medical needs in oncology and neurodegeneration. In 2000, the company was acquired by Signal Pharmaceuticals, which subsequently became part of Celgene. The legacy of its research contributed to the broader kinase inhibitor portfolios of its successor organizations.